As of Nov 19, 2026, 1 of 1 active firms rate DARE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DARE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.24
Range $-0.24 – $-0.24 · 1 analysts · +139% YoY
Next period, 1 analysts expect Dare Bioscience Inc to earn $-0.24 a share (range $-0.24 – $-0.24), versus $-0.10 a year earlier. Full-year consensus is $-0.70, growing to $-0.53 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $4.0M, rising to $7.4M next year.
Top analysts covering Dare Bioscience Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DARE.
#1
Douglas Tsao
HC Wainwright & Co. · Rank #312
Buy
$12.00+2566.1% to target
Overall win rate
35%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #567
Buy
$8.00+1677.4% to target
Overall win rate
30%
+ Follow
#3
CP
Caroline Palomeque
Maxim Group
Buy
$8.00+1677.4% to target
Coverage
—
+ Follow
#4
KD
Kemp Dolliver
Brookline Capital Markets
Buy
$11.00+2343.9% to target
Coverage
—
+ Follow
DARE stock forecast FAQ
What is DARE's average 12-month price target?+
The 1 active firms with a live target average $12.00 for Dare Bioscience Inc over the next 12 months, ranging from a $12.00 high to a $12.00 low, as of Nov 19, 2026.
Is DARE stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover DARE?+
1 active firms have a recognized rating on Dare Bioscience Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DARE?+
Among analysts who currently cover DARE, Douglas Tsao of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #312). Their current call is Buy with a $12.00 target.
What is Dare Bioscience Inc's projected EPS for next quarter?+
The consensus estimate is $-0.24 per share (range $-0.24 – $-0.24) across 1 analysts. Full-year EPS is projected at $-0.70, rising to $-0.53 the following year.
How much revenue is Dare Bioscience Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $4.0M, growing to $7.4M next year.
Have analysts been upgrading or downgrading DARE lately?+
As of Nov 19, 2026, 1 of 1 active firms rate DARE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DARE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.